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Acute or chronic injury to the central nervous system (CNS), causes neuronal death
and irreversible cognitive deficits or sensory-motor alteration. Despite the capacity
of the adult CNS to generate new neurons from neural stem cells (NSC), neuronal
replacement following an injury is a restricted process, which does not naturally result
in functional regeneration. Therefore, potentiating endogenous neurogenesis is one
of the strategies that are currently being under study to regenerate damaged brain
tissue. The insignificant neurogenesis that occurs in CNS injuries is a consequence
of the gliogenic/non-neurogenic environment that inflammatory signaling molecules
create within the injured area. The modification of the extracellular signals to generate
a neurogenic environment would facilitate neuronal replacement. However, in order
to generate this environment, it is necessary to unearth which molecules promote or
impair neurogenesis to introduce the first and/or eliminate the latter. Specific isozymes
of the protein kinase C (PKC) family differentially contribute to generate a gliogenic
or neurogenic environment in injuries by regulating the ADAM17 mediated release
of growth factor receptor ligands. Recent reports describe several non-tumorigenic
diterpenes isolated from plants of the Euphorbia genus, which specifically modulate the
activity of PKC isozymes promoting neurogenesis. Diterpenes with 12-deoxyphorbol
or lathyrane skeleton, increase NPC proliferation in neurogenic niches in the adult
mouse brain in a PKCβ dependent manner exerting their effects on transit amplifying
cells, whereas PKC inhibition in injuries promotes neurogenesis. Thus, compounds that
balance PKC activity in injuries might be of use in the development of new drugs and
therapeutic strategies to regenerate brain injuries.
Keywords: protein kinase C, neurogenesis, ADAM17/TACE, brain injury, neuroregeneration
NEUROGENESIS IN THE ADULT BRAIN UNDER
PHYSIOLOGICAL CONDITIONS
Cell replacement in several mammalian organs is an orchestrated process that may lead to the
regeneration of a completely functional organ. Unfortunately, this is not the case of the adult central
nervous system (CNS). Neurogenesis, the process of generation of new neurons that occurs during
development of the CNS and remains during the infant and adult stages is built up on the capacity
of neural stem cells (NSC) to produce neurons and glial cells. Yet quiescent NSC are distributed
ubiquitously along the adult CNS (Magavi et al., 2000), once development is ended, neurogenesis is
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restricted to a few specific regions. In these areas NSC produce
neurons because they are situated in a context of signaling
molecules that induce their transition to an activated state,
from which they produce a progeny mainly comprised of
cells with a neuronal phenotype. Two neurogenic regions
have been thoroughly described in the adult mammalian
brain, the subventricular zone (SVZ) and the dentate gyrus
of hippocampus (DG) (Kuhn et al., 1996; Doetsch et al.,
1997). Within these regions an environment of extracellular
signaling molecules creates a neurogenic niche that preserves
the necessary conditions to support neurogenesis during a
lifetime. Different cell types derived from the NSC progeny
can be distinguished within these niches: undifferentiated
neural progenitor cells (NPC) produced by activated NSC,
and neuronal progenitor cells (neuroblasts) that differentiate
into mature neurons. Since the potentiality of NPC is almost
identical to that of NSC, they can produce either neuronal
progenitors or glial progenitors (Reynolds and Weiss, 1992;
Doetsch et al., 1999; Torroglosa et al., 2007). However, once
in the niche, extracellular, matrix-bound and membrane-bound
signals determine their fate toward a neuronal phenotype
(Codega et al., 2014).
INJURY-INDUCED NEUROGENESIS
Adult neurogenesis has generated a great deal of attention in
the context of designing cell replacement therapies following
neuronal loss. Focal traumatic or cerebrovascular brain injuries
cause acute damage, induce neuronal death and irreversible
cognitive deficits or sensory-motor alterations (Blennow et al.,
2012). No effective treatment is currently available to compensate
neuronal loss in these patients, however, the potential of the CNS
to generate new neurons that replace the lost ones has opened
a new perspective in the development of therapies to treat this
type of lesions. One of the strategies, currently under study,
to enable neuronal replacement is facilitating the recruitment
of endogenous NPC and neuroblasts within the injured tissue
(Saha et al., 2012). Two different sources of neuroblasts facilitate
neuronal replacement in injuries: NPC generated from NSC
activated at the site of injury (Magavi et al., 2000; Chen et al., 2004;
Geribaldi-Doldan et al., 2018) and NPC or actual neuroblasts
that are generated in neurogenic regions as a reaction to the
damage, which migrate in the direction of the injury (Parent
et al., 1997; Arvidsson et al., 2002; Kandasamy et al., 2015;
Geribaldi-Doldan et al., 2018). However, cells from both sources
would need an adequate environment to survive and to lead their
destiny toward mature neurons that would integrate into existing
neuronal circuits (Romero-Grimaldi et al., 2011). Following an
injury, neurogenic regions react activating different steps of the
neurogenic process: activation of quiescent NSC, induction of
NPC proliferation, differentiation, and alteration of neuroblast
migration patterns (Liu et al., 1998; Fallon et al., 2000; Jin et al.,
2001) in the direction of the injured area. However, this attempt
to repair the damaged tissue is generally unsuccessful and most
of the originated NPC lead the destiny of their progeny toward
astroglial cells (gliogenesis) rather than neurons (neurogenesis)
(Romero-Grimaldi et al., 2011; Susarla et al., 2014; Geribaldi-
Doldan et al., 2018). The lack of significant neurogenesis in
damaged brain areas, even when endogenous NPC are available,
may be due to the absence of molecules necessary for neuronal
differentiation and/or to the presence of molecules that favor
the differentiation of NPC toward a glial phenotype (Benner
et al., 2013). Inflammatory molecules released mainly by glial and
microglial cells create a gliogenic/non-neurogenic environment
that facilitates the generation of glial progenitor cells, which
differentiate into glial cells (Buffo et al., 2008). Thus, it may be
possible that these glial cells activate a paracrine positive feedback
loop that favors gliogenesis from NPC over neurogenesis.
NEURONAL REPLACEMENT
STRATEGIES: PROMOTION OF
ENDOGENOUS NEUROGENESIS
Potentiating endogenous neurogenesis is one of the strategies
that are currently being under study to regenerate damaged brain
tissue. Four important stages of the neurogenic process can be
modulated in order to promote endogenous neurogenesis: (1)
to stimulate NSC activation and proliferation of NPC within
the lesion (Luzzati et al., 2014; Barker et al., 2018), (2) to
generate an environment that favors neurogenesis in neurogenic
regions to lead the fate of NPC into a neuronal phenotype
(Parent et al., 1997; Grade and Gotz, 2017), (3) to promote
migration of neuroblasts toward the damaged areas, as well as
survival (Geribaldi-Doldan et al., 2018), and (4) to stimulate
differentiation of neuroblasts into mature neurons (Geribaldi-
Doldan et al., 2018) facilitating the posterior integration of the
newly generated neurons into preexisting circuits. In summary,
replacement of dead neurons in an injured CNS region requires
the modification of the extracellular environment to generate
a neurogenic niche in which the progeny of endogenous NSC
is predominantly mature functional neurons. However, it is
first necessary to uncertain which molecules promote or impair
neurogenesis and introduce the first and/or eliminate the latter.
Recent reports aimed to understand the cellular and molecular
mechanisms involved in the generation of this gliogenic/non-
neurogenic background highlight the key role of neurogenic
signaling molecules such as Noggin (Lim et al., 2000) or
Neuregulin 1 (NRG1) that promotes neuroblast migration,
and gliogenic signaling pathways such as those initiated by
Notch (Benner et al., 2013), or the epidermal growth factor
receptor (EGFR) (Kuhn et al., 1997; Gonzalez-Perez et al., 2009;
Romero-Grimaldi et al., 2011; Geribaldi-Doldan et al., 2018)
among other signals.
It is worth mentioning the essential role of EGFR activation
in the neurogenic processes. EGFR signaling participates in
SVZ neurogenesis promoting proliferation of undifferentiated
transit amplifying progenitors (TAPs) (Doetsch et al., 2002;
Torroglosa et al., 2007). In NPC cultures under differentiation
conditions, EGFR activation favors gliogenesis over neurogenesis
(Romero-Grimaldi et al., 2011). In brain injuries, the shedding
of EGFR ligands such as TGFα activate EGFR and prevent the
generation of neurons facilitating gliogenesis and contributing
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to the generation of gliogenic niches in areas of brain damage
(Romero-Grimaldi et al., 2011; Geribaldi-Doldan et al., 2018).
Regulating EGFR activity might be relevant when developing
strategies to promote endogenous neurogenesis in brain injuries
and understanding the mechanisms that activate this receptor
may lead to the identification of molecular targets to regenerate
brain injuries. Thus, in the subsequent paragraphs, we will
discuss molecular mechanisms involved in the regulation
of EGFR activity.
ADAM17/TACE DEPENDENT EGFR
LIGAND RELEASE
As commented above, epidermal growth factor (EGF)–induced
EGFR activation, in cultures of NPC isolated from the SVZ,
promotes glial cell differentiation whereas EGFR inhibition
facilitates the differentiation of these cells toward a neuronal
phenotype (Romero-Grimaldi et al., 2011). The effect of
the EGFR inhibition can be mimicked in vitro by the
inhibition of the tumor necrosis factor alpha-converting enzyme
(ADAM17/TACE), a metalloprotease of the A Disintegrin
And Metalloproteinase (ADAM) family. These metalloproteases
catalyze the cleavage of the extracellular domains (ectodomains)
of several EGFR ligands. These ligands are synthesized as
membrane-anchored precursor proteins (pro-ligands). The
active soluble ligands are detached from the pro-ligands and
released to the extracellular medium in a proteolytic reaction
catalyzed by convertases of the ADAM family. In particular TGFα
release is mediated by ADAM17 (Blobel, 2005), a membrane-
bound peptidase, which is a limiting step in regulating signaling
through EGFR. ADAM17 is the main convertase involved in
the release of the EGFR ligands TGFα, HB-EGF, Epiregulin
and Amphiregulin (Sunnarborg et al., 2002; Lee et al., 2003).
Nevertheless, ADAM17 also catalyzes the release of other ligands
of the ErbB family of receptors (Figure 1A). The selectivity of this
enzyme for each ligand is mediated by phosphorylation reactions
in the C-terminal domain of the pro-ligand, catalyzed by kinases
of the protein kinase C (PKC) family (Dang et al., 2013).
PKC ISOZYMES STRUCTURE AND
CLASSIFICATION
Kinases of the PKC family are enzymes composed of regulatory
and catalytic domains (Figure 1B), which phosphorylate a great
variety of substrates. These proteins remain in an inactivated
state that can be reverted upon the binding of their regulators
diacylglycerol (DAG), calcium and phosphatidyl serine (PS) to
the regulatory domains. They are characterized by a conserved
kinase domain, which undergoes a conformational change and
activates itself to enable catalysis. As shown in Table 1, kinases
of the PKC family play an essential role in transducing signals
related with cell cycle entrance, differentiation, apoptosis or
autophagy among other functions (Watanabe et al., 1992;
Dempsey et al., 2000; Black and Black, 2012). This family of
proteins consists of ten serine-threonine kinases, which based
on their regulatory domains and physiological activators, are
classified in three subfamilies (Mellor and Parker, 1998): the
classical, the novel and the atypical. The classical PKCs (α, β,
and γ), depend on calcium, DAG, and PS for their activation.
The novel PKCs (δ, ε, θ, and η), are calcium independent kinases
but they still require DAG and PS for their activation. The
atypical PKC (λ and ζ) do not depend on calcium or DAG for
their activation and are regulated by protein-protein interactions
(Rosse et al., 2010; Figure 1B).
PKC AND THERAPEUTIC
CONSIDERATIONS
The above-mentioned role of PKC isozymes in regulating
ADAM17 activity may lead to hypothesize that modulating PKC
activity might be of use as a treatment to promote endogenous
neurogenesis in lesions. However, therapeutic considerations
may be taken into account because of the strong association of
these kinases in cancer or neurodegenerative diseases such as
Alzheimer’s disease (AD) (reviewed in Newton, 2018a; Table 1).
Almost all PKC isozymes have been associated with tumor
progression and also with the metastasis process. Classical PKC
are involved in tumorigenicity, for example PKCα regulates cell
motility in some cancer models and some authors described a
relationship between up or down-regulation of these isozyme
depending of the type of cancer (Konopatskaya and Poole, 2010).
PKCβ II induces endothelial cells proliferation and stimulates
tumor angiogenesis in breast cancer, whereby some inhibitors
of this isozyme have been postulated as a therapeutic treatment
(Sledge and Gokmen-Polar, 2006) for this type of cancer. Novel
PKCδ has been associated with pro-apoptotic signaling, in fact it
is involved in tumor suppression inhibiting cell cycle progression
(Basu and Pal, 2010). PKCε is one of the most studied isozymes
in cancer research with a significant role in lung cancer (Baxter
et al., 1992). PKCθ has been implicated is gastrointestinal cancer
(Ou et al., 2008). Atypical PKC as PKCζ is involved in breast
cancer development and in promoting glioma initiating cells
proliferation, invasion and migration (Huang et al., 2012; Malla
et al., 2012). It is important to clarify that in general, a reduced
PKC activity and protein expression has been associated to
different types of cancer.
This reduced activity in tumors contrasts with the
enhanced PKC activity and expression found in models of
neurodegenerative diseases such as AD or stroke (Table 1)
(reviewed in Sun and Alkon (2014), Newton (2018a)). Acute
and chronic changes in PKC activity can be found in models of
AD, stroke and age-dependent neurodegeneration with different
effects depending on the disease and the stage of the disease. As
the body ages, activity and proper translocation of PKC isozymes
is critical for memory, and injury repair (Table 1) (reviewed in
Lucke-Wold et al., 2015). Gain of function mutations of classical
PKCα activity has been specifically involved in the reduction of
synaptic activity caused by AD (Alfonso et al., 2016) contributing
to cognitive decline. In a similar fashion, inhibition of novel
PKCδ reduces amyloid ß and reverses AD (Du et al., 2018).
Alteration on PKC expression can also be observed as aging
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FIGURE 1 | Structure of PKC isozymes and their indirect role in EGFR activation. (A) Cartoon representing the sequence of PKC-ADAM17-TGFα-EGFR pathway.
Binding of DAG or non-physiological diterpenes to the regulatory domains of PKC activates the enzymes. Upon activation, enzymes are translocated close to the
plasma membrane where they catalyze the phosphorylation of membrane bound EGFR pro-ligands or ligands of other receptors of the ERBB family (i.e., neuregulin)
or ligands that activate other receptors, (i.e., neuregulin, which activates ERBB4). Only phosphorylated pro-ligands are selected by ADAM17 as substrates over other
non-phosphorylated ones. ADAM17-mediated shedding occurs on the phosphorylated pro-ligands, releasing the soluble ligand and activating the receptor.
(B) Classification of PKC isozymes according to their structure and regulatory properties. Regulatory domains (C1 and C2) and binding sites for regulatory molecules
(DAG, Ca2+, and PS) are shown as well as the conserved catalytic domains (C3 and C4). ∗See structure of Diacylglicerol below; ∗∗See structures of different
diterpenes (PMA, ER272 and ELAC) below.
occurs and a downregulation in PKC expression is found
in different models probably as a consequence of epigenetic
modifications (Pascale et al., 2007). Whether these alterations are
the basis of the disease or a homeostatic response to the disorders
remains to be clarified.
PKC, ADAM17 AND EGFR: ROLE IN
ADULT NEUROGENESIS
Protein kinase C isozymes phosphorylate several downstream
substrates including EGFR ligands as well as other ErbB receptor
ligands such as NRG1. Specific activation of PKC isozymes
determines ADAM17 selectivity for its different substrates
(Figure 1A). Thus, PKCα activated by Phorbol-12-myristate-
13-acetate (PMA) catalyzes the phosphorylation of TGFα,
Amphiregulin and HB-EGF precursors facilitating their shedding
mediated by ADAM17 and releasing the soluble growth factor
outside the cell (Dang et al., 2013). On the contrary, activation
of novel PKCδ is required for ADAM17 mediated secretion
of NRG1. Phosphorylation of serine 286 in the cytoplasmic
domain of NRG1 catalyzed by PKCδ facilitates the scission of its
ectodomain (Watanabe et al., 1992; Dang et al., 2011) releasing
NRG1 into the extracellular medium. Overall, ADAM17 substrate
specificity and selectivity is mediated by the activation of different
PKC isozymes, which play a key role in the secretion of different
types of ligands (Dang et al., 2011, 2013) governing several steps
of adult neurogenesis. As examples, autocrine secretion of TGFα
in brain injuries leads NPC toward a glial fate preventing the
generation of neurons; on the contrary, inhibition of ADAM17
dramatically increases the generation of neurons (Romero-
Grimaldi et al., 2011; Geribaldi-Doldan et al., 2018). NRG1
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TABLE 1 | Pathophysiological role of PKC isozymes.
PKC isoforms Tissue expression Functions Reference
Classical PKCs
α Ubiquitous • Cell proliferation and metastasis Heart failure,
decreased contractility.
• Apoptosis, tumorigenecity, cell adhesion,
differentiation, migration.
• Synaptic defects in AD.
• Role in learning and memory.
Konopatskaya and Poole, 2010; Liu and
Molkentin, 2011; Sun and Alkon, 2014; Alfonso
et al., 2016; Singh et al., 2017
β Ubiquitous • Cancer development: vasculogenesis and cell
invasion.
• Diabetes: vascular complications.
Sledge and Gokmen-Polar, 2006; Geraldes and
King, 2010
γ Brain and spinal cord • Pain modulation in dorsal root ganglia.
• Long term potentiation, long term depression,
modulation of receptors, neurological disorder.
Saito and Shirai, 2002; Sweitzer et al., 2004
Novel PKCs
δ Ubiquitous • Proliferation, immune function, apoptosis, and
cell migration.
• Fertility.
• Cancer development: angiogenesis.
• Regulation of amyloid-β degradation pathway.
• Neuronal loss in animal models of Parkinson’s
Disease
Zhang et al., 2007; Reyland, 2009; Basu and
Pal, 2010; Ma et al., 2015; Du et al., 2018
ε Ubiquitous • Heart failure, increased fibrosis, ischemia,
mitochondria protection.
• Pain modulation in spinal cord.
• Bipolar diseases: neuronal transmission
malfunction.
• Role in learning and memory.
• Ischemic tolerance
Sweitzer et al., 2004; Inagaki et al., 2006; Einat
et al., 2007; Liu et al., 2012;
Sun and Alkon, 2014
η Ubiquitous • Acquired resistance to radiation.
• Epithelial cell growth and differentiation.
Kraft et al., 1982; Cabodi et al., 2000
θ Ubiquitous • Gastrointestinal stromal tumor, cell proliferation
and antiapoptosis.
• T cell responses, inflammation.
Ou et al., 2008; Zanin-Zhorov et al., 2011
Atypical PKCs
λ Ubiquitous • Glioblastoma cell invasion. Baldwin et al., 2008
ζ Ubiquitous • Breast cancer cell metastasis.
• Glioma, cell proliferation, survival, invasion, and
migration.
Van Kolen and Slegers, 2006; Guo et al., 2009;
Huang et al., 2012
mediated activation of ErbB4 promotes neurogenesis in the adult
SVZ increasing NPC proliferation and organizing migration of
neuroblasts from the SVZ toward the olfactory bulb (Anton et al.,
2004; Ghashghaei et al., 2006). These evidences point out at the
mission of specific kinases of PKC family on stimulating the
production of signaling molecules such as TGFα or NRG1 (Dang
et al., 2011, 2013), which may have a decisive role in leading
NSC and NPC toward gliogenesis or neurogenesis, respectively
(Ghashghaei et al., 2006; Romero-Grimaldi et al., 2011).
PKC ISOZYMES IN ADULT
NEUROGENESIS
Several members of the PKC family are present in neurogenic
regions (Minami et al., 2000) and participate in distinct signaling
cascades initiated by growth factors (GF), often determining
GF specificity (Corbit et al., 2000). Activation of classical
PKCß promotes proliferation of NPC in vitro and induces
the expression of cyclins E and D in the absence of EGFR.
In vivo in the SVZ and DG of mice, PKC activation promotes
proliferation (Geribaldi-Doldan et al., 2016; Murillo-Carretero
et al., 2017) mainly of EGFR+ transit amplifying cells. In
addition, atypical PKC have been involved in the NSC-to-
neuron transition during development, and in the adult brain
(Wang et al., 2012). On the contrary, novel PKCε, activation
is crucial for the astrocytic differentiation of NPC (Steinhart
et al., 2007). Phosphorylation of the CREB binding protein
(CBP) by atypical PKC promotes hippocampal neurogenesis as
well as memory and learning in mature adult mice in which
CREB activity is reduced as a consequence of age (Gouveia
et al., 2016). Metformin-induced activation of atypical PKC
in mice promotes hippocampal neurogenesis and enhances
spatial reversal learning in the Morris Water Maze task (Wang
et al., 2012). Furthermore, local treatment of mechanical
brain injuries with a pan-PKC inhibitor, promotes neuroblast
enrichment facilitating differentiation of NPC toward neurons
(García-Bernal et al., 2018). Overall, activation of classical PKC
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isozymes promotes neurogenesis in neurogenic regions whereas
its inhibition facilitates neurogenesis in injuries.
PKC ACTIVATION BY DITERPENES
The physiological activator of PKC is DAG; this molecule
binds to the C1B domain of classical and novel PKC isozymes
(Figure 1B) inducing a conformational change that results in
the activation of the protein. The affinity of PKC isozymes for
DAG is higher in novel PKC than in classical PKC isozymes
(reviewed in Newton, 2018b). Non-physiological molecules such
as phorbol esters can activate classical and novel PKC isozymes.
These tetracyclic diterpenoids activate PKC because they mimic
the action of diacylglycerol (DAG) (Newton, 1995) binding to
the same regulatory domain with different affinities. The most
commonly used diterpene with phorbol ester structure is PMA.
This phorboid has been extensively tested as a potent activator of
PKC (Deleers and Malaisse, 1982). It binds to the C1B domain
in PKC and promotes its translocation to the plasma membrane
(Newton, 1995); unfortunately, it lacks of clinical use due to
being a very potent tumor promoter (Szallasi and Blumberg,
1991). Its tumor-promoting activity seems to be associated to
the nature and extent of the reversibility of PKC activation
(Newton, 2018b), which in parallel is associated to the affinity
of this molecules for the C1B domain and the effect of these
molecules on the translocation of PKC to the plasma membrane.
Thus, phorbol esters with more lipophilic substituents have a
higher affinity for the C1B domain and lock PKC in an open
(active) conformation on the membrane. This results in their
dephosphorylation and subsequent degradation of the protein,
a process referred to as down–regulation (Hansra et al., 1999).
However, other diterpenes with a more hydrophobic character
(Wang et al., 1999; Wang et al., 2000; Braun et al., 2005) reversibly
activate PKC and this translates into signaling events that
generate different kinds of cell responses (Murphy et al., 1999).
This is the case of prostratin (13-O-acetyl-12-deoxyphorbol) a
commercially available 12-deoxyphorbol initially isolated from
the plant Homalanthus nutans (Márquez et al., 2008) or other 12-
deoxyphorbols isolated from plants of the Euphorbia genus like
ER272 (12-deoxyphorbol-13-isobutyrate) (Schmidt and Evans,
1977; Fatope et al., 1996; Kirby et al., 2010). The mechanisms
underlying tumor promoting activity of PKC remain unknown,
although it is possible that this downregulation is responsible
for the tumor promoting activity (Newton, 2018b). Therefore, as
it has been previously proposed by Newton (2018a,b), phorbol
esters with more hydrophobic side chains like prostratin or
other 12-deoxyphorbols (Schmidt and Evans, 1977; Fatope et al.,
1996; Kirby et al., 2010) may lead to balance PKC activity
generating the desired biological responses in the absence of
tumorigenic activity.
Protein kinase C inhibitors have also been used in the
literature to treat specific CNS injuries (Wang et al., 2014;
García-Bernal et al., 2018; Tang et al., 2018). Specific inhibitors
that target one PKC isozyme can only be found for classical
PKCß (Lesyk et al., 2015) and atypical PKCζ (Puls et al.,
1997; Bogard and Tavalin, 2015). On the contrary the majority
of commercially available PKC inhibitors target a group of
isozymes showing a smaller IC50 for classical PKCα and β. No
specific inhibitors target novel PKCs alone without affecting other
classical isozymes. Classical PKC inhibitors have been used to
repair cervical dorsal spinal hemisection (Wang et al., 2014) and
mechanical cortical injuries (García-Bernal et al., 2018), whereas
peptide induce inhibition of novel PKCδ has been effective
in the treatment of damage of the blood brain barrier (Tang
et al., 2018). The molecular mechanisms underlying the effects
of the inhibitors are not clear in some cases, because of the
lack of specificity.
DITERPENES, PKC AND
NEUROGENESIS
Non-tumor promoting diterpenes with 12-deoxyphorbol or
lathyrane structure exert a proliferative effect on NPC cultures
in vitro (Geribaldi-Doldan et al., 2016; Murillo-Carretero et al.,
2017). Interestingly, whereas 12-deoxyphorbols promote NPC
proliferation in vitro independently of their structure, not all
lathyranes are able to exert this effect and only 3,12-di-O-acetyl-
8-O-tigloilingol (ELAC) induces a classical PKC dependent effect
on NPC proliferation. Treatment of NPC cultures with 12-
deoxyphorbols in the absence of EGF increases proliferation
promoting cyclin D and E expression mimicking the effects of
EGF signaling. This sustains the hypothesis of a PKC dependent
release of EGFR ligands (Geribaldi-Doldan et al., 2016; Murillo-
Carretero et al., 2017). Additionally, intracerebroventricular
administration of diterpenes such as the 12-deoxyphorbols like
prostratin or ER272, and the diterpene with lathyrane skeleton
ELAC, increase NPC proliferation in neurogenic niches in the
adult mouse brain in a PKC dependent manner (Geribaldi-
Doldan et al., 2016; Murillo-Carretero et al., 2017). The cellular
and molecular mechanisms underlying the proliferative effect
of these compounds have also been investigated and it is
the specific activation of classical PKCβ what promotes the
proliferation of EGFR+ transit amplifying cells in the SVZ
(Murillo-Carretero et al., 2017).
CONCLUSION
Regulating EGFR activity might be relevant when developing
strategies to promote endogenous neurogenesis in brain injuries.
A limiting step in this activation is the metalloprotease ADAM17,
which is regulated by PKC. We have discussed in here how
different PKC isozymes govern different steps of the neurogenic
process in different niches, concluding that PKC might be a
target to promote neurogenesis in injuries. Non-tumorigenic
diterpenes with 12-deoxyphorbol or lathyrane skeleton activate
PKC and increase NPC proliferation in adult neurogenic niches
by activating classical PKC. Diterpenes with the capacity to
activate classical PKC might be the active principle of useful
drugs to treat disorders that require potentiation of neurogenesis
(aging, AD, or Huntington’s disease among other). Because of
their capacity to reversibly activate PKC, diterpenes are better
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drugs than other PKC activators that promote tumor growth.
However, specific activators of each PKC isozymes need to
be discovered in the short future that could be used to treat
diverse CNS disorders in which PKC isozymes are differentially
expressed and regulated. On the contrary, inhibition of classical
PKC in injuries, thus maintaining novel PKC activities may lead
to a limited release of EGFR ligands favoring the generation
of new neurons over glial cells. Therefore, finding non-
tumorigenic activators of each specific PKC isozyme, which
facilitate adjustment of the homeostatic balances of PKC activity,
will definitely lead to the development of new drugs and
therapeutic strategies to regenerate brain injuries.
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